Pfizer Pulls Out Additional Lots Of It Anti-Smoking Pill

by Vandana Singh, Benzinga Editor

August 17, 2021 12:29 PM | 1 min read |

Impurity concerns have prompted Pfizer Inc PFE to pull another four Chantix lots in the U.S., bringing up to 16 batches of its total recall.
The latest action covers a quartet of 0.5/1-mg tablets, and as earlier Chantix recalls, this too stems from impurities discovered in the drugs that are above Pfizer's approved daily limit.
Related: FDA Supports Limited Distribution Of Pfizer's Antismoking Pill, Chantix.
Multiple Chantix doses are currently in shortage as the company conducts product testing, the FDA says.
In the meantime, the regulator has summoned Apotex to export its generic Chantix product from Canada to the States.
Related content: Benzinga's Full FDA Calendar.
Price Action: PFE shares are up 0.61% at $49.20 during the market session on the last check Tuesday.

Posted In:

Biotech News Health Care FDA General anti-smoking Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.